Tim Gronniger, MPP, MHSA, senior vice president of development and strategy at Caravan Health, discusses the struggles that organizations face when attempting to make a switch to new payment models, and how that switch can be improved in the future.
Tim Gronniger, MPP, MHSA, senior vice president of development and strategy at Caravan Health, discusses the struggles that organizations face when attempting to make a switch to new payment models, and how that switch can be improved in the future.
Transcript
What have been some of the biggest barriers for organizations trying to implement new payment models?
Relationships within an organization and with physicians in the community are one of the first things that you have to figure out, and a lot of that comes up under the rubric of governance structures. Who’s going to be making the decisions about the ACOs performance, and who’s going to be making decisions about who’s doing what about who the leaders of it are? And, then, technology ends up dominating a lot of discussion time as well. How are we getting all of our information in one data warehouse if we’re building an ACO with our independent community network of physicians? Then, there might be 50 EMO products in that network, so we have to find a way where can at least pull data from that set of vendors, if not, push and pull that data. So, getting a good handle on IT and technology and analytics takes a lot of time early on in an ACO.
What changes do you think need to be made to improve the move to value-based payment models?
The changes that we need to see are really consistent policy direction from Washington around what they want the health system to do first. A way to enable providers who are working together on improving quality in trackable form ensure, that is going to continue into the future and avoid unforced errors, such as cancellation of a mandatory bundle payment programs last year, anything that would upset the Applecart in terms of the Medicare Shared Savings Program, where we could see a huge withdrawal if the agency moves to promote risk too aggressively. Now, I said earlier, we all know that risk-bearing models are the future and Medicare Shared Savings Program, but trying to make the future happen in 6 months is a recipe for confusion and turmoil, not a recipe for success. I’m all for the agency being aggressive on risk-bearing models, but it needs to be done in a stepwise fashion.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
Amid Debate Over Diversity, RCC Trials Still Struggle to Reflect Patient Populations
February 16th 2025Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing challenge with enrolling diverse patient populations in trials, despite stated goals.
Read More